Your session is about to expire
← Back to Search
Live Attenuated Tularemia Vaccine for Tularemia (NDBR Trial)
NDBR Trial Summary
This trial will test the safety and effectiveness of a new tularemia vaccine.
NDBR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NDBR Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this research encompass participants aged 40 or above?
"The upper age limit for participants in this trial is 65 years old, while the minimum age of consent applies."
Is enrollment for this research project still open?
"Data on clinicaltrials.gov displays that this medical trial is not actively enrolling participants right now, as the last update was made in February 2021. However, there are presently other trials accepting applicants."
What potential hazards should be considered when administering Live Attenuated Tularemia Vaccine?
"Our team has judged the safety of Live Attenuated Tularemia Vaccine to be a 2. This is due to its status as a Phase 2 trial which demonstrates some data supporting safety, but no evidence for efficacy."
Who meets the criteria to partake in this research endeavor?
"This medical trial is recruiting 500 subjects suffering from tularemia, all of whom should be within the age range 18-65. Criteria for applicant acceptance include risk exposure to Francisella tularensis (Ftularensis) and a signed Request for IND Vaccines regarding their vaccine status, agreement to report any adverse events 28 days after administration or serious consequences during study duration, submission to follow-up visits, clearance by an investigator with possible exams/tests repeat at PI's discretion, deferment of blood donation in 1 year post vaccination."
Share this study with friends
Copy Link
Messenger